Fairhaven Pharmaceuticals Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.79M

Fairhaven Pharmaceuticals General Information

Description

Fairhaven Pharmaceuticals was a developer of oral therapeutics intended to treat severe inflammatory conditions. The company used to offer a preclinical research program of small molecule antagonists and other related services to develop oral therapeutics, enabling clinicians to treat patients with inflammatory conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1917 West 4th Avenue
  • Suite 390
  • Vancouver, British Columbia
  • Canada
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 1917 West 4th Avenue
  • Suite 390
  • Vancouver, British Columbia
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fairhaven Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 16-Jul-2020 $2.79M Completed Generating Revenue
1. Early Stage VC Completed Generating Revenue
To view Fairhaven Pharmaceuticals’s complete valuation and funding history, request access »

Fairhaven Pharmaceuticals Patents

Fairhaven Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022417301-A1 Oxer1 antagonists and uses thereof Pending 20-Dec-2021
CA-3240538-A1 Oxer1 antagonists and uses thereof Pending 20-Dec-2021
EP-4452940-A1 Oxer1 antagonists and uses thereof Pending 20-Dec-2021
EP-4452940-A4 Oxer1 antagonists and uses thereof Pending 20-Dec-2021
JP-2025503491-A Oxer1 antagonists and uses thereof Pending 20-Dec-2021 C07D471/04
To view Fairhaven Pharmaceuticals’s complete patent history, request access »

Fairhaven Pharmaceuticals Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
AmorChem Venture Capital Minority
Genesys Capital Venture Capital Minority
To view Fairhaven Pharmaceuticals’s complete investors history, request access »

Fairhaven Pharmaceuticals FAQs

  • Where is Fairhaven Pharmaceuticals headquartered?

    Fairhaven Pharmaceuticals is headquartered in Vancouver, Canada.

  • What industry is Fairhaven Pharmaceuticals in?

    Fairhaven Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Fairhaven Pharmaceuticals a private or public company?

    Fairhaven Pharmaceuticals is a Private company.

  • What is the current valuation of Fairhaven Pharmaceuticals?

    The current valuation of Fairhaven Pharmaceuticals is .

  • What is Fairhaven Pharmaceuticals’s current revenue?

    The current revenue for Fairhaven Pharmaceuticals is .

  • Who are Fairhaven Pharmaceuticals’s investors?

    AmorChem and Genesys Capital have invested in Fairhaven Pharmaceuticals.

  • When was Fairhaven Pharmaceuticals acquired?

    Fairhaven Pharmaceuticals was acquired on 16-Jul-2020.

  • Who acquired Fairhaven Pharmaceuticals?

    Fairhaven Pharmaceuticals was acquired by Liminal Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process